MarketCapExport financials
Iovance Biotherapeutics (IOVA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Iovance Biotherapeutics Balance Sheet 2025-2007 | IOVA
Brief overview of Iovance Biotherapeutics's balance sheet strength
This overview follows the five latest available annual observations between 2021 and 2025.
Assets added +17.5%, reaching $913.2 million from $777.3 million five periods earlier; annual growth near 4.1% remained solid.
Liabilities expanded faster than the asset base, +37.8% versus +17.5%. Debt-service capacity deserves attention.
Equity accounts for 76.5% of assets. Against the initial 80%, the capital position looks resilient.
Negative net debt of -$114.6 million means cash holdings are larger than debt obligations.
Cash equals 17.9% of the balance sheet, compared with 10.1% five periods ago. This is the readily available cushion.
Retained earnings are negative at -$2.8 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Overall assessment
Taken together, the figures indicate acceptable resilience for Iovance Biotherapeutics. The next assessment depends on debt and equity trends.
Annual Balance Sheet Iovance Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-115 M | -58.4 M | -40 M | -147 M | -7.7 M | -15.7 M | -2.47 M | -82.2 M | -145 M | -107 M | -13.6 M | -44.9 M | -19.7 M | 6.48 M | 4.49 M | - | - | - | - |
Long Term Debt |
44.4 M | 44.4 M | 67.1 M | 71.9 M | 65.5 M | 45.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
4.04 M | 12.9 M | 7.78 M | 12.6 M | 5.06 M | 6.28 M | 7.25 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
76.2 M | 77.7 M | 85.4 M | 72.9 M | 66.5 M | 57.1 M | 6.6 M | 230 K | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
138 M | 122 M | 110 M | 91.5 M | 89.2 M | 54.9 M | 39.1 M | 14.4 M | 9.89 M | 4.97 M | 1.63 M | 1.66 M | 2.27 M | 11.3 M | 13.3 M | 823 K | - | - | - |
Total Liabilities |
215 M | 200 M | 196 M | 164 M | 156 M | 112 M | 45.7 M | 14.6 M | 9.89 M | 4.97 M | 1.63 M | 1.66 M | 2.27 M | 11.3 M | 13.3 M | - | - | - | - |
Retained Earnings |
-2.78 B | -2.38 B | -2.01 B | -1.57 B | -1.17 B | -830 M | -571 M | -373 M | -249 M | -157 M | -104 M | -76.6 M | -64.5 M | -30.7 M | -27.4 M | -1.68 M | - | - | - |
Total Assets |
913 M | 910 M | 780 M | 664 M | 777 M | 768 M | 345 M | 481 M | 155 M | 172 M | 106 M | 46.5 M | 19.9 M | 29.4 K | 568 K | 1.46 M | - | - | - |
Cash and Cash Equivalents |
163 M | 116 M | 115 M | 232 M | 78.2 M | 67.3 M | 14 M | 82.2 M | 145 M | 107 M | 33.6 M | 44.9 M | 19.7 M | - | 510 K | 1.29 M | 8.26 K | 2.9 K | - |
Book Value |
699 M | 710 M | 585 M | 500 M | 622 M | 656 M | 299 M | 466 M | 145 M | 167 M | 104 M | 44.8 M | 17.6 M | -11.3 M | -12.8 M | 1.46 M | - | - | - |
Total Shareholders Equity |
699 M | 710 M | 585 M | 500 M | 622 M | 656 M | 299 M | 466 M | 145 M | 167 M | 104 M | 44.8 M | 17.6 M | -11.3 M | -12.8 M | 638 K | -13.5 K | 2.28 K | 8 K |
All numbers in USD currency
Quarterly Balance Sheet Iovance Biotherapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
43.3 M | 43.9 M | 45.2 M | 45.1 M | 44.2 M | 44.4 M | 66.4 M | 69.2 M | 72.3 M | 67.1 M | 68 M | 68.8 M | 69.6 M | 71.9 M | 71.9 M | - | 71.2 M | 65.5 M | 64.7 M | 46.8 M | 47.1 M | 45.4 M | 45.4 M | 45.4 M | 45.4 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
72.6 M | 74.5 M | 76.9 M | 79.8 M | 76.2 M | 77.7 M | 99.6 M | 102 M | 107 M | 85.4 M | 87.4 M | 90.1 M | 70.6 M | 72.9 M | 72.9 M | - | 72.2 M | 66.5 M | 65.7 M | 47.8 M | 48.1 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 230 K | 230 K | 230 K | 230 K | 297 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
179 M | 204 M | 203 M | 209 M | 199 M | 200 M | 218 M | 196 M | 190 M | 196 M | 178 M | 179 M | 158 M | 164 M | 152 M | - | 149 M | 156 M | 130 M | 108 M | 103 M | 112 M | 112 M | 112 M | 112 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 9.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.9 B | -2.85 B | -2.7 B | -2.61 B | -2.5 B | -2.38 B | -2.31 B | -2.22 B | -2.13 B | -2.01 B | -1.9 B | -1.78 B | -1.68 B | -1.57 B | -1.46 B | - | -1.26 B | -1.17 B | -1.07 B | -987 M | -906 M | -830 M | -830 M | -830 M | -830 M | -571 M | -571 M | -571 M | -571 M | -373 M | -373 M | -373 M | -373 M | -249 M | -249 M | -249 M | -249 M | -157 M | -157 M | -157 M | -157 M | -104 M | -104 M | -104 M | -104 M | -76.6 M | -76.6 M | -76.6 M | -76.6 M | -64.5 M | -64.5 M | -64.5 M | -64.5 M | -30.7 M | -30.7 M | -30.7 M | -30.7 M | -27.4 M | -27.4 M | -27.4 M | -27.4 M |
Total Assets |
916 M | 926 M | 905 M | 907 M | 967 M | 910 M | 991 M | 964 M | 870 M | 780 M | 852 M | 757 M | 825 M | 664 M | 546 M | - | 701 M | 777 M | 829 M | 853 M | 751 M | 768 M | 768 M | 768 M | 768 M | 345 M | 345 M | 345 M | 345 M | 481 M | 481 M | 481 M | 481 M | 155 M | 155 M | 155 M | 155 M | 172 M | 172 M | 172 M | 172 M | 106 M | 106 M | 106 M | 106 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 29.4 K | 29.4 K | 29.4 K | 29.4 K | 568 K | 568 K | 568 K | 568 K |
Cash and Cash Equivalents |
111 M | 197 M | 158 M | 132 M | 172 M | 116 M | 164 M | 229 M | 134 M | 115 M | 268 M | 230 M | 543 M | 232 M | 118 M | 108 M | 92.4 M | 78.2 M | 58.6 M | 82.8 M | 132 M | 67.3 M | 67.3 M | 67.3 M | 67.3 M | 14 M | 14 M | 14 M | 14 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 145 M | 145 M | 145 M | 145 M | 107 M | 107 M | 107 M | 107 M | 33.6 M | 33.6 M | 13.6 M | 13.6 M | 44.9 M | 44.9 M | 44.9 M | 44.9 M | 19.7 M | 19.7 M | 19.7 M | 19.7 M | - | - | 15.5 K | - | 510 K | 510 K | 510 K | 510 K |
Book Value |
736 M | 722 M | 702 M | 698 M | 768 M | 710 M | 773 M | 769 M | 680 M | 585 M | 674 M | 579 M | 667 M | 500 M | 394 M | - | 552 M | 622 M | 698 M | 744 M | 647 M | 656 M | 656 M | 656 M | 656 M | 299 M | 299 M | 299 M | 299 M | 466 M | 466 M | 466 M | 466 M | 145 M | 155 M | 155 M | 155 M | 172 M | 172 M | 172 M | 172 M | 106 M | 106 M | 106 M | 106 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 29.4 K | 29.4 K | 29.4 K | 29.4 K | 568 K | 568 K | 568 K | 568 K |
Total Shareholders Equity |
736 M | 722 M | 702 M | 698 M | 768 M | 710 M | 773 M | 769 M | 680 M | 585 M | 674 M | 579 M | 667 M | 500 M | 394 M | 473 M | 552 M | 622 M | 698 M | 744 M | 647 M | 656 M | 656 M | 656 M | 656 M | 299 M | 299 M | 299 M | 299 M | 466 M | 466 M | 466 M | 466 M | 145 M | 145 M | 145 M | 145 M | 167 M | 167 M | 167 M | 167 M | 104 M | 104 M | 104 M | 104 M | 44.8 M | 44.8 M | 44.8 M | 44.8 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | -11.3 M | -11.3 M | -11.3 M | -11.3 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Iovance Biotherapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
- | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
$ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alector
ALEC
|
$ 2.19 | 2.1 % | $ 226 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.08 | 0.96 % | $ 50.2 M | USA |
 |
Alkermes plc
ALKS
|
$ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.79 | 0.28 % | $ 395 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 248.37 | 0.14 % | $ 32.5 B | USA |
 |
Altimmune
ALT
|
$ 3.31 | 1.22 % | $ 292 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.93 | 0.52 % | $ 104 M | USA |
 |
Amgen
AMGN
|
$ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
$ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
$ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.76 | 2.03 % | $ 4.97 M | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.87 | 2.75 % | $ 590 K | USA |
 |
AbCellera Biologics
ABCL
|
$ 11.04 | 1.38 % | $ 3.3 B |  Canada |
 |
Aquestive Therapeutics
AQST
|
$ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
$ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Artelo Biosciences
ARTL
|
$ 5.15 | 1.1 % | $ 974 K | USA |
 |
Arvinas
ARVN
|
$ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 28.86 | 0.64 % | $ 324 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.25 | 6.87 % | $ 39 M | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
$ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | 1.26 % | $ 2.19 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
$ 5.34 | 0.47 % | $ 435 M | USA |
 |
Axon Enterprise
AXON
|
$ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
$ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
$ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
$ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
$ 2.03 | 2.52 % | $ 115 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 24.35 | 1.5 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
$ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.48 | 0.2 % | $ 6.11 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
$ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
$ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.11 | 0.08 % | $ 498 M | USA |
 |
Burford Capital Limited
BUR
|
$ 4.35 | 1.13 % | $ 953 M | Britain |